热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　玮俊生物科技（00660）公布，公司建议实施以下涉及股本削减及股份拆细的资本重组如下：

　　（i）通过注销每股当时已发行现有普通股的缴足股本0.25港元，削减公司的已发行股本，从而使每股已发行现有普通股的面值从0.25港元减少至0.01港元；及

　　（ii）紧随股本削减后，每股面值0.25港元的法定但未发行股份（包括因股本削减而产生的法定但未发行股份）将拆细为25股每股面值0.01港元的新普通股。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.